Chi-Med gears up for China NDA after surufatinib hits phase III endpoint in NET Oct. 3, 2019 By David Ho No Comments HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) is preparing for the next step after surufatinib achieved its primary endpoint in a phase III SANET-ep study in extra-pancreatic advanced neuroendocrine tumors (NETs) in China.Read More